Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

doi:10.2217/pgs.14.140

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

Pharmacogenomics - 1 Dec 2014

Allegrini Giacomo, Coltelli Luigi, Orlandi Paola, Fontana Andrea, Camerini Andrea, Ferro Antonella, Cazzaniga Marina, Casadei Virginia, Lucchesi Sara, Bona Eleonora, Di Lieto Marco, Pazzagli Ilaria, Villa Federica, Amoroso Domenico, Scalese Marco, Arrighi Giada, Molinaro Sabrina, Fioravanti Anna, Finale Chiara, Triolo Renza, Di Desidero Teresa, Donati Sara, Marcucci Lorenzo, Goletti Orlando, Del Re Marzia, Salvadori Barbara, Ferrarini Ilaria, Danesi Romano, Falcone Alfredo, Bocci Guido

Abstract excerpt

AIM: To investigate pharmacogenetic interactions among VEGF-A, VEGFR-2, IL-8, HIF-1α, EPAS-1 and TSP-1 SNPs and their role on progression-free survival in a population of metastatic breast cancer patients treated with bevacizumab in combination with first-line paclitaxel. PATIENTS & METHODS: Analyses were performed on germline DNA obtained from blood samples and SNPs were investigated by real-time polymerase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Basic Helix-Loop-Helix Transcription Factors

Share to Bevacizumab

Share to Hypoxia-Inducible Factor 1, alpha Subunit

Share to Interleukin-8

Share to Paclitaxel

Share to Thrombospondin 1

Share to Vascular Endothelial Growth Factor Receptor-2

Source

Open in PubMed

Identifiers

PMID: 25521357
DOI: 10.2217/pgs.14.140

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.PMID 25521357Read ↗

Bevacizumab and Paclitaxel in Advanced, Hormone Receptor-Positive Breast Cancer: Multifactor Dimensionality Reduction Methodology to Identify Best Overall Survival.Semantic proximity Read ↗

Genetic variability of VEGF pathway genes in six randomized phase III trials assessing the addition of bevacizumab to standard therapy.Semantic proximity Read ↗

Interaction among variant vascular endothelial growth factor (VEGF) and its receptor in relation to prostate cancer risk.Semantic proximity Read ↗

Genetic interaction of P2X7 receptor and VEGFR-2 polymorphisms identifies a favorable prognostic profile in prostate cancer patients.Semantic proximity Read ↗

Methodological issues in detecting gene-gene interactions in breast cancer susceptibility: a population-based study in Ontario.Semantic proximity Read ↗

Breast cancer-associated high-order SNP-SNP interaction of CXCL12/CXCR4-related genes by an improved multifactor dimensionality reduction (MDR-ER).Semantic proximity Read ↗

Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer.Semantic proximity Read ↗

Combined Genotype Effects of TP53 and PAI-1 Polymorphisms in Breast Cancer Susceptibility: Multifactor Dimensionality Reduction and in silico Analysis.Semantic proximity Read ↗

Risk of GWAS-identified genetic variants for breast cancer in a Chinese population: a multiple interaction analysis.Semantic proximity Read ↗

Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQuinto study.Semantic proximity Read ↗

A multigenic approach to predict breast cancer risk.Semantic proximity Read ↗

Combined effects of IL-8 and CXCR2 gene polymorphisms on breast cancer susceptibility and aggressiveness.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.